Latest Articles

Publication Date
Does the cause matter? - a comparison of endometriosis-related dyspareunia to dyspareunia of other origin.

Published: Sept. 19, 2026, midnight
Psychometrics of the Deep and Superficial Dyspareunia Questionnaire: test-retest reliability, discriminant validity, and convergent validity.

Published: Sept. 15, 2026, midnight
Chronic abdominal pain and dyspareunia in endometriosis: pain therapy with a nerve and muscle stimulation device with biofeedback function.

Endometriosis (EM) is frequently associated with chronic pelvic pain (CPP) and dyspareunia, often linked to secondary pelvic floor dysfunction and hypertonicity. To evaluate whether the use of an intravaginal electromyography …

Published: Sept. 15, 2026, midnight
The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications.

Endometriosis is a chronic gynecological disorder affecting approximately 10% of reproductive-age women, characterized by the ectopic growth of endometrial tissue and severe pain, including dysmenorrhea, chronic pelvic pain, dyspareunia, dysuria, …

Published: Sept. 15, 2026, midnight
Presumed Hippocampal Endometriosis Presenting as Catamenial Epilepsy: Diagnostic Challenges, MRI Follow-Up, and Comparative Review of Reported Cerebral Endometriosis Case.

Background: Cerebral endometriosis is an exceptionally rare manifestation of extrapelvic endometriosis and remains a diagnostic challenge because its clinical and imaging features may mimic more common neurological, inflammatory, vascular, or …

Published: Sept. 11, 2026, midnight
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of Linustedastat (OG-6219) in Women with Moderate to Severe Endometriosis-Related Pain.

Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estradiol biosynthesis. …

Published: Sept. 9, 2026, midnight
Modulating the Estrobolome and Inflammatory Microenvironment in Endometriosis: The Role of Microbiome-Targeted Interventions and Nutritional Compounds.

Endometriosis is a chronic estrogen-dependent systemic inflammatory disorder characterized by ectopic implantation of endometrial-like tissue, primarily on the ovaries, pelvic peritoneum, and bowel. According to the World Health Organization (WHO) …

Published: Sept. 3, 2026, midnight
Three- and Four-Dimensional Pelvic Floor Ultrasound in Chronic Pelvic Pain: Evidence, Technical Considerations, and a Proposed Framework.

Chronic pelvic pain (CPP) is a heterogeneous condition in which visceral, musculoskeletal, neuropathic, and pain-processing contributors often overlap. Pelvic floor ultrasound can depict morphology and movement, but its CPP-specific evidence …

Published: Sept. 1, 2026, midnight
Exploring Short-Acting Hormonal Contraceptives in Endometriosis Care-A Narrative Review and Evidence-Based Practical Considerations.

Endometriosis is a chronic, estrogen-dependent inflammatory condition affecting approximately 10% of women of reproductive age and manifesting with pelvic pain, dysmenorrhea, dyspareunia, fatigue, and infertility. First-line treatment in most patients …

Published: Aug. 30, 2026, midnight
Physical rehabilitation and sexual function in endometriosis: a systematic review and meta-analysis.

Endometriosis is a chronic gynecological disease associated with pelvic pain and dyspareunia that negatively affects sexual function. Physical rehabilitation programs have emerged as a non-pharmacological therapeutic alternative; however, evidence regarding …

Published: Aug. 29, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!